ONCOBIX CO LTD has a total of 13 patent applications. It increased the IP activity by 700.0%. Its first patent ever was published in 2017. It filed its patents most often in Republic of Korea, WIPO (World Intellectual Property Organization) and Australia. Its main competitors in its focus markets pharmaceuticals and organic fine chemistry are CELGENE QUANTICEL RESEARCH INC, ABAC THERAPEUTICS S L and RELAY THERAPEUTICS INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | Republic of Korea | 5 | |
#2 | WIPO (World Intellectual Property Organization) | 2 | |
#3 | Australia | 1 | |
#4 | Brazil | 1 | |
#5 | Canada | 1 | |
#6 | China | 1 | |
#7 | EPO (European Patent Office) | 1 | |
#8 | Russian Federation | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Heterocyclic compounds | |
#3 | Therapeutic chemical compounds |
# | Name | Total Patents |
---|---|---|
#1 | Ryu Hyung Chul | 10 |
#2 | Rajesh Rengasamy | 9 |
#3 | Kim Kyong Cheol | 9 |
#4 | Kang Dae Ho | 8 |
#5 | Kim Sung-Eun | 7 |
#6 | Lee Jae Cheol | 7 |
#7 | Kim Jae-Sun | 7 |
#8 | Rho Jin Kyung | 7 |
#9 | Lee Sunho | 6 |
#10 | Lee Sangryul | 6 |
Publication | Filing date | Title |
---|---|---|
WO2020256477A1 | Pyrimidine derivative inhibiting growth of cancer cell and medicinal use thereof | |
KR102168179B1 | Novel pyrimidine derivative showing growth inhibition of cancer cell and pharmaceutical composition comprising the same | |
KR20210016103A | Novel compound for inducing degradation of alk protein and pharmaceutical composition for using in preventing or treating cancer containing the same as an active ingredient | |
WO2019112344A1 | Novel pyrimidine derivative having effect of inhibiting cancer cell growth and pharmaceutical composition containing same | |
KR20190067699A | Novel pyrimidine derivative showing growth inhibition of cancer cell and pharmaceutical composition comprising the same | |
KR20190003242A | Fused pyrimidine derivative as a mutant Epidermal Growth Factor Receptor kinase inhibitor |